--- title: 'Regulatory Daily Summary: What Happened on November 9, 2026' headline: FDA approves Bayer stroke drug, rejects Novocure cancer application description: The agency added a possible eye-risk warning to GLP-1 labels and cleared an injected antibody treatment for recurrent head and neck cancer. url: https://thebench.bio/news/regulatory/2026-11-09 topic: regulatory date: '2026-11-09' covers: - '2026-11-09' date_published: '2026-11-09T12:02:33Z' date_modified: '2026-11-10T00:01:50Z' tags: - Regulatory - Industry - Funding - Research sources: 13 publisher: TheBench.Bio --- # Regulatory Daily Summary: What Happened on November 9, 2026 **FDA approves Bayer stroke drug, rejects Novocure cancer application** The agency added a possible eye-risk warning to GLP-1 labels and cleared an injected antibody treatment for recurrent head and neck cancer. ## Today in brief Bayer’s Sunharbo became the first Factor XIa inhibitor approved to reduce stroke risk, while the FDA rejected Novocure’s metastatic cancer application. [1] [2] [3] The FDA also ordered an eye-condition warning on GLP-1 labels and authorized an antibody treatment given under the skin for recurrent head and neck cancer. [4] [5] [6] ## FDA approves Bayer’s Sunharbo to prevent recurrent stroke The FDA approved Sunharbo with antiplatelet therapy for adults at risk of another stroke after a recent mild-to-moderate ischemic stroke or a high-risk transient ischemic attack. [1] It is the first Factor XIa inhibitor approved for this use. [1] In the Phase 3 OCEANIC-STROKE trial, Sunharbo reduced ischemic stroke risk by 26% compared with placebo, with both groups also receiving antiplatelet therapy. [1] Another stroke occurred in 6.2% of Sunharbo recipients and 8.4% of placebo recipients. [7] Major bleeding rates were similar overall, but higher with Sunharbo among patients older than 75 and during the first 90 days of treatment. [1] Gastrointestinal bleeding was also more common, and diarrhea was the most frequently reported adverse reaction. [1] The FDA advises against combining Sunharbo with certain drugs, including carbamazepine, or using it in patients with moderate or severe liver impairment. [1] Sunharbo isn’t approved to prevent stroke in people with atrial fibrillation. The FDA advises pausing it before elective procedures and after thrombolysis for acute ischemic stroke. [1] ## FDA adds potential vision risk to GLP-1 labels The FDA is requiring class-wide label changes warning that GLP-1 medicines may be associated with non-arteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause sudden vision loss. [4] [5] Labels will tell patients to report sudden vision changes and recommend referral to an eye specialist when NAION is suspected. [5] Clinicians may consider stopping treatment if NAION occurs, unless the benefits clearly outweigh the risks. The warning is not boxed. [5] Evidence on the risk is mixed. An FDA analysis found no statistically significant increase versus SGLT-2 inhibitors, but a 43% higher risk versus DPP-4 inhibitors. [5] A pooled analysis of 126 trials found 15 probable cases, 10 among GLP-1 users, with rates of 6.4 versus 3.8 cases per 100,000 person-years in comparison patients. [5] Other studies reached different results. A U.S. health-record analysis found 76% higher risk among semaglutide or tirzepatide users, while a Cleveland Clinic analysis found no statistically significant increase. [5] The FDA said animal data showed no mechanism linking the medicines to NAION and that adverse-event reports were difficult to interpret because risk factors are common among users. [5] Novo Nordisk said the evidence does not establish cause and effect. The FDA said observational research consistently found higher risk among new GLP-1 users with type 2 diabetes than among patients starting comparator drugs. [5] ## FDA rejects Novocure’s metastatic cancer treatment The FDA denied Novocure approval for its metastatic cancer treatment. [3] Novocure said the agency was uncertain about the degree of clinical benefit for brain metastases. [3] ## Also worth knowing - The U.S. imposed new rules for ordering synthetic DNA to deter bioterrorism. Biosecurity experts gave the policy tempered praise. [8] - The MHRA awarded Innovation Passports to three investigational medicines for Huntington’s disease, non-small cell lung cancer and early Alzheimer’s disease. They remain in development, and any future availability depends on evidence of safety, effectiveness and value. [9] - China authorized Bio-Thera’s BAT2506, sold as Ashuli, for ankylosing spondylitis and rheumatoid arthritis. It is the country’s first approved biosimilar to Simponi. [10] - A Vital Transformation analysis linked the Inflation Reduction Act’s introduction with a 37% drop in follow-on small-molecule oncology studies, a 27% decline in lead-indication approvals and a 14% decrease in the share of oncology studies focused on orphan indications. [11] - The FDA invited public comment on a discussion paper about medical robots with autonomous or remote-operation functions as it develops policy for the devices. [12] - Treasury proposed COINS Act regulations that could make it harder for U.S.-backed companies to pursue Chinese biotech assets while potentially giving European drugmakers more room to do so. [13] ## The day in numbers - **26%**: Lower ischemic stroke risk with Sunharbo than placebo in the Phase 3 trial. [1] [7] - **6.2% vs. 8.4%**: Share of Sunharbo and placebo recipients, respectively, who had another stroke in the trial. [7] - **37%**: Reduction in follow-on small-molecule oncology studies associated with the IRA’s introduction in the Vital Transformation analysis. [11] - **3**: Investigational medicines granted MHRA Innovation Passports. [9] ## Also published - [AMP President: AI, Regulation, and Labor Shortages Threaten Molecular Diagnostics](), Inside Precision Medicine - [Simulation-Guided Clinical Trials: Is EU Law Ready?](), MedCity News - [MHRA grants Innovation Passports to three novel drugs](), pharmaphorum - [How China Cut Its Phase III Startup Timeline and What Drove the Change](), Applied Clinical Trials - [Rationalizing Biological Drug Development: Biosimilar Science, Modality-Specific Pathways, and the Bioprocessing Revolution, Part 2](), BioProcess International ## Sources 1. [FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk](), FDA Press Announcements, 2026-11-09 2. [Bayer wins FDA nod for a new kind of blood thinner](), BioPharma Dive, 2026-11-09 3. [Novocure denied FDA approval for metastatic cancer treatment](), MedTech Dive, 2026-11-09 4. [STAT+: FDA warns GLP-1 drugs carry potential risk of rare eye condition](), STAT Biotech, 2026-11-09 5. [FDA’s GLP-1 vision warning rests on mixed evidence](), Drug Discovery and Development, 2026-11-09 6. [ACT Brief: APAC Inspection Findings, RBQM Key Risk Indicators, and Head and Neck Cancer Approval](), Applied Clinical Trials, 2026-11-09 7. [STAT+: FDA approves novel Bayer drug to reduce recurrence of stroke](), STAT Biotech, 2026-11-09 8. [To deter bioterrorism, U.S. imposes new rules on ordering synthetic DNA](), Science News, 2026-11-09 9. [Investigational treatments for lung cancer, Huntington’s disease and Alzheimer's gain Innovation Passports through the Innovative Licensing and Access Pathway ](), MHRA, 2026-11-09 10. [Bio-Thera gains Chinese approval for spondylitis and rheumatoid arthritis drug](), Pharmaceutical Technology, 2026-11-09 11. [Cancer drug study puts numbers to the cost of IRA’s pill penalty](), Bio.News, 2026-11-09 12. [FDA seeks input on telesurgery, autonomous robotics](), MedTech Dive, 2026-11-09 13. [Could new U.S. rules on China biotech investments give Europe an edge?](), PharmaVoice, 2026-11-09 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: [7]: [8]: [9]: [10]: [11]: [12]: [13]: